Catecholamines In Normal And Abnormal Cardiac Function

An International Symposium "Catecholamines and the Heart" was held in Munich in May 1981, which was organized in cooperation with the Council on Cardiac Metabolism of the International Society and Federation of Cardiology and with the Microcirculation Working Group of the European Society of Cardiology. It was the aim of the organizers to evaluate in this Symposium the recent advances made in the field of sympathetic control of heart function. Particular attention was given to neural sympathetic pathways, to mechanisms and consequences of adrenoceptor stimulation and blockade as well as to clinically relevant implications mainly regarding the significance of catecholamines and of adrenoceptors in various heart diseases. The broad scope was covered in 34 papers presented by physiologists, pharmacologists and cardiologists during a two day meeting which was attended by an international audience. This book includes all papers as well as the discussions following each presentation. To accomplish rapid publication the manuscripts are published as submitted by the authors. The discussions were edited making use of the written questions and answers of the discussants. The Symposium was generously sponsored by Astra Chemicals GmbH, Wedell Holstein, Germany, which thus made possible a very fruitful exchange of information, ideas and concepts between specialists in various disciplines. The organizers gratefully acknowledge this support once again and would like to thank Dr. T. Kreuzer, the representative of Astra Chemicals, for his personal engagement.

A concise, in-depth analysis of the status of the sympathetic system in heart diseases This book summarizes the functional status of the sympathetic neural system in cardiological diseased states and highlights aspects of sympathetic neural activity that are important to an overall understanding of the pathophysiology process. Critical reviews of methods for evaluating sympathetic activity are discussed, existing data is closely scrutinized, and attempts are made to delineate the factors derived from increased sympathetic activity. The book provides a physiologically and clinically based approach to the investigation of the involvement of catecholamines in cardiovascular diseases, which makes it a valuable addition to the reference collections of researchers, clinical scientists, and graduate students.

Research centering on blood flow in the heart continues to hold an important position, especially since a better understanding of the subject may help reduce the incidence of coronary arterial disease and heart attacks. This book summarizes recent advances in the field; it is the product of fruitful cooperation among international scientists who met in Japan in May, 1990 to discuss the regulation of coronary blood flow.

This book outlines some new advances in genetics, clinical evaluation, localization, therapy (newly including immunotherapy) of pheochromocytoma and paraganglioma including their metastatic counterparts. Well-known and experienced clinicians and scientists contributed to this book to include some novel approaches to these tumors. This book will serve to various health care professionals from different subspecialties, but mainly oncologists, endocrinologists, endocrine surgeons, pediatricians, and radiologists. This book shows that the field of pheochromocytoma/paraganglioma is evolving and a significant progress has been made in last 5 years requiring that health care professionals and scientists will learns new information and implement it in their clinical practice or scientific work, respectively. This book should not be missed by anybody who is focusing on neuroendocrine tumors, their newest evaluation and treatment.

Caffeine in Food and Dietary Supplements is the summary of a workshop convened by the Institute of Medicine in August 2013 to review the available science on safe levels of caffeine consumption in foods, beverages, and dietary supplements and to identify data gaps. Scientists with expertise in food safety, nutrition, pharmacology, psychology, toxicology, and related disciplines; medical professionals with pediatric and adult patient experience in cardiology, neurology, and psychiatry; public health professionals; food industry representatives; regulatory experts; and consumer advocates discussed the safety of caffeine in food and dietary supplements, including, but not limited to, caffeinated beverage products, and identified data gaps. Caffeine, a central nervous stimulant, is arguably the most frequently ingested pharmacologically active substance in the world. Occurring naturally in more than 60 plants, including coffee beans, tea leaves, cola nuts and cocoa pods, caffeine has been part of innumerable cultures for centuries. But the caffeine-in-food landscape is changing. There are an array of new caffeine-containing energy products, from waffles to sunflower seeds, jelly beans to syrup, even bottled water, entering the marketplace. Years of scientific research have shown that moderate consumption by healthy adults of products containing naturally-occurring caffeine is not associated with adverse health effects. The changing caffeine landscape raises concerns about safety and whether any of these new products might be targeting populations not normally associated with caffeine consumption, namely children and adolescents, and whether caffeine poses a greater health risk to those populations than it does for healthy adults. This report delineates vulnerable populations who may be at risk from caffeine exposure; describes caffeine exposure and risk of cardiovascular and other health effects on vulnerable populations, including additive effects with other ingredients and effects related to pre-existing conditions; explores safe caffeine exposure levels for general and vulnerable populations; and identifies data gaps on caffeine stimulant effects.